HARVARD BIOSCIENCE INC

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

HBIO$9.26+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders' Equity

HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited, in thousands)
Accumulated
Number · Additional · Other · Total
	of Shares	Common	Paid-in	Accumulated	Comprehensive	Stockholders’
	Issued *	Stock	Capital	Deficit	Loss	Equity
Balance at December 31, 2025	4,472	$447	$239,669	$(214,710)	$(11,672)	$13,734
Warrant exercises	30	-	150	-	-	150
Vesting of restricted stock units	14	-	-	-	-	-
Shares withheld for taxes	(5)	-	(30)	-	-	(30)
Stock-based compensation	-	-	257	-	-	257
Net loss	-	-	-	(3,424)	-	(3,424)
Other comprehensive loss	-	-	-	-	(641)	(641)
Balance at March 31, 2026	4,511	$447	$240,046	$(218,134)	$(12,313)	$10,046

Accumulated
Number · Additional · Other · Total
	of Shares	Common	Paid-in	Accumulated	Comprehensive	Stockholders’
	Issued *	Stock	Capital	Deficit	Loss	Equity
Balance at December 31, 2024	4,407	$441	$236,579	$(158,010)	$(15,670)	$63,340
Vesting of restricted stock units	25	1	-	-	-	1
Shares withheld for taxes	(11)	-	(75)	-	-	(75)
Stock-based compensation	-	-	600	-	-	600
Net loss	-	-	-	(50,340)	-	(50,340)
Other comprehensive income	-	-	-	-	1,309	1,309
Balance at March 31, 2025	4,421	$442	$237,104	$(208,350)	$(14,361)	$14,835

*	Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13,2026.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.